Clinical trials: Steatosis
Infant Obesity, Hepatic Steatosis
TREating Pediatric Obesity
The main aim of the study is to collect preliminary information on the feasibility and efficacy of a time restricted eating intervention in Spanish children and adolescents with obesity and metabolic comorbidities.
- Conditions
- Infant Obesity, Hepatic Steatosis, Metabolic Syndrome, Insulin Resistance
- Trial name
- TREPO (NCT05124847)
- Testing
- Standard Care, Time restricted eating
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Healthy, Metabolic Dysfunction-associated Steatohepatitis
A Study to Test How Well Different Doses of BI 3804379 Are Tolerated by Healthy People and Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH)
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PKs) of BI 3804379 in healthy male and female participants and in stable patients with advanced liver fibrosis due to MASH following…
- Trial name
- NCT06575400
- Testing
- BI 3804379
- Where
- Belgium
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
NAFLD, NASH
LITMUS Imaging Study
The LITMUS Imaging Study is a prospectively recruited, observational study of patients with histologically characterised non-alcoholic fatty liver disease (NAFLD).
- Conditions
- NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver
- Trial name
- NCT05479721
- Where
- 18 sites in United States, Finland and 8 more
- Volunteers
- 450 people
- Sponsor
- University of Oxford
Non-alcoholic Steatohepatitis, Liver Diseases
Reducing Non-Alcoholic Steatohepatitis
The goal of this clinical trial is to learn if empagliflozin works to treat non-alcoholic steatohepatitis in adults. The objectives are: Primary Objective To evaluate the change in histological grading and staging of NASH in…
- Conditions
- Non-alcoholic Steatohepatitis, Liver Diseases, Diabetes Mellitus, Type 2, Fibrosis, Liver
- Trial name
- RedNASH (NCT06519448)
- Testing
- Empagliflozin 10 miligrams (mg)
- Where
- Czechia
- Volunteers
- 30 people
- Sponsor
- Military University Hospital, Prague
Non-alcoholic Fatty Liver Disease
Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of diseases ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), the progressive form of liver disease that can lead to cirrhosis and liver-related…
- Trial name
- NCT01963845
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Pediatric Obesity, Metabolic Syndrome
Cardio-Metabolic Risk Evaluation in Overweight and Obese Children
Metabolic and cardio-vascular complications can often appear in overweight and obese children from an early age. Currently, there are few studies in the specialized literature that correlate clinical, biological and ultrasound…
- Conditions
- Pediatric Obesity, Metabolic Syndrome, Nonalcoholic Fatty Liver, Atherosclerosis
- Trial name
- CardMetSOb (NCT05908877)
- Testing
- History and Clinical evaluation, Biological evaluation of the metabolic syndrome and components, Ultrasound evaluation of subclinical atherosclerosis and visceral fat storage
- Where
- Romania
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Neoped - Centru de Pediatrie
Non-alcoholic Fatty Liver Disease (NAFLD), Weight Loss
Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults
Non-alcoholic fatty liver disease (NAFLD) is defined by presence of hepatic steatosis (fat accumulation in liver cells), either by imaging or by biopsy and absence of causes for secondary hepatic fat accumulation such as…
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD), Weight Loss, Non-alcoholic Steatohepatitis (NASH)
- Trial name
- CGH-LiNASH (NCT02654665)
- Testing
- Lifestyle modification, Liraglutide
- Where
- Singapore
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Changi General Hospital
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Role of a Wheat Containing Diet on Non-alcoholic Steatohepatitis
Effects of Wheat-based diet vs. ATI-free diet on NASH
- Conditions
- NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2, Hyperlipidemias
- Trial name
- NASH-ATI (NCT04066400)
- Testing
- Nutritional Intervention
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Johannes Gutenberg University Mainz
Non-alcoholic Steatohepatitis, Chronic Liver Disease
Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures
The purpose of this study is to assess the ability of eltrombopag to elevate platelet counts thereby reducing the need for platelet transfusions in chronic liver disease patients with thrombocytopenia undergoing elective invasive…
- Conditions
- Non-alcoholic Steatohepatitis, Chronic Liver Disease, HCV, NASH - Nonalcoholic Steatohepatitis
- Trial name
- ELEVATE (NCT00678587)
- Testing
- Eltrombopag
- Where
- 107 sites in United States, Argentina and 11 more
- Volunteers
- 292 people
- Sponsor
- GlaxoSmithKline
Morbid Obesity, Non-alcoholic Fatty Liver Disease
Effect of Macrocomposition on Nonalcoholic Fatty Liver Disease (NAFLD) in Bariatric Surgery Candidates
Nonalcoholic Liver disease (NAFLD) is known to be caused by deposition of fat in the liver. The impact of NAFLD on bariatric surgery is of great concern.
- Trial name
- NCT00887393
- Testing
- low carbohydrate diet, low-fat diet
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Michigan
NAFLD
Effect of Mediterranean Diet on Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is a clinical/biochemical condition associated with the metabolic syndrome. As the disease stems from excess calorie intake and lack of physical activity, the correction of unhealthy…
- Trial name
- Nutriepa (NCT01798719)
- Testing
- Low Glycemic Index Mediterranean Diet, General Advice
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
NAFLD
Effects of Tomato Products in Children With NAFLD
CONTROLLED TRIAL ON THE EFFECT OF TOMATO PRODUCTS IN OBESE CHILDREN WITH NON ALCOHOLIC FATTY LIVER DISEASE Aim of the study To evaluate the effect of the addition of a daily dose of lycopene enriched tomato sauce on the progress…
- Trial name
- NCT03463967
- Testing
- Lycopene-enriched tomato juice, Energy-restricted diet
- Where
- Italy
- Volunteers
- 61 people
- Sponsor
- Federico II University
Morbid Obesity, Non-alcoholic Fatty Liver Disease
Intestinal Microbiota and NAFLD Pre and Post Bariatric Surgery
Non-alcoholic fatty liver disease (NAFLD) includes benign hepatic simple steatosis (SS) and steatohepatitis (NASH), which is characterised by inflammation leading to fibrosis and cirrhosis.
- Trial name
- NCT01856465
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Johane Allard
NAFLD (Non-Alcoholic Fatty Liver Disease), Resistance Training
The Role of Resistance Training in Non Alcoholic Fatty Liver Disease
The aim of the study is to evaluate the effect of RT on clinical and metabolic parameters in patients with NAFLD.
- Trial name
- NCT01264198
- Testing
- Resistance Training
- Where
- Israel
- Volunteers
- 82 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Healthy Participants
Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy Participants
This Phase I, randomised, single-blind, placebo-controlled study has been designed to assess the safety, tolerability, and pharmacokinetics (PK) of AZD2693 following subcutaneous (SC) administration of AZD2693 in healthy…
- Trial name
- NCT05107336
- Testing
- AZD2693
- Where
- Japan
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
Phase 2b Study of GSK4532990 in Adults With NASH
The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4).
- Trial name
- HORIZON (NCT05583344)
- Testing
- GSK4532990
- Where
- 170 sites in United States, Argentina and 15 more
- Volunteers
- 284 people
- Sponsor
- GlaxoSmithKline
Steatohepatitis, Nonalcoholic, Hemosiderosis
The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) Pediatric Patients
The prevalence of liver steatosis, steatohepatitis, fibrosis, and hemosiderosis in overweight and obese US Military dependent pediatric patients using MR Elastography and Quantitative MRI
- Conditions
- Steatohepatitis, Nonalcoholic, Hemosiderosis, Overweight Adolescents, Obesity, Childhood
- Trial name
- NCT04284371
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- The Geneva Foundation
Non-Alcoholic Fatty Liver Disease
Impact of Cold Exposure on Metabolic Regulation in Children With Non Alcoholic Fatty Liver Disease (NAFLD)
The aim of this project is to generate pilot data for a grant proposal to evaluate the impact of intermittent cold exposure (ICE) on brown and white adipose tissue (BAT/WAT) function in children with non-alcoholic fatty liver…
- Trial name
- ICE BAT (NCT04969744)
- Testing
- ICE
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Fatty Liver, Nonalcoholic, NAFLD
A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
Randomized, double-blind, placebo-controlled, parallel-group study comparing multiple doses of HTD1801 to placebo.
- Conditions
- Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
- Trial name
- NCT03656744
- Testing
- HTD1801
- Where
- 17 sites in United States
- Volunteers
- 101 people
- Sponsor
- HighTide Therapeutics (Hong Kong) Limited
Fatty Liver, Dyslipidemias
Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease
The purpose of the study is to compare the impact of atorvastatin 20mg qd and Vitamin E 300mg qd therapy on liver fat content in patients with type 2 diabetes associated with high LDL-C and non-alcoholic fatty liver disease.
- Conditions
- Fatty Liver, Dyslipidemias, Diabetes Mellitus
- Trial name
- NCT01720719
- Testing
- atorvastatin, Vitamin E
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xin Gao
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.